Celldex Therapeutics reported $11.45M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.58B 316M Mar/2026
Agenus USD 10.56M 13.04M Dec/2025
Amgen USD 1.58B 354M Mar/2026
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
Celldex Therapeutics USD 11.45M 3.61M Mar/2026
Glaxosmithkline GBP 3.56B 650.29M Dec/2025
Nektar Therapeutics USD 10.17M 10.17M Dec/2025
Northwest Biotherapeutics USD 7.07M 1.06M Sep/2025
Pfizer USD 2.92B 1.16B Mar/2026
Rigel Pharmaceuticals USD 27.04M 1M Sep/2024
Roche Holding CHF 7.28B 3.99B Dec/2025